

Anti-CD94 Antibodies for Enhanced Immune Response to Cancer Cells

Tech ID: 33619 / UC Case 2020-221-0

TECHNOLOGY DESCRIPTION

Current cancer therapies often have limitations such as off-target effects, development of resistance, and limited efficacy against certain cancer types. There is a pressing need for therapies that can specifically target cancer cells and enhance the body's natural immune response against these malignant cells. The inventors have developed a novel therapeutic approach that uses anti-CD94 antibodies to deplete NK cells in a cancer patient.

APPLICATION

This method enhances the targeting and killing of cancer cells by activated T cells, such as CD8+ effector T cells. The anti-CD94 antibodies can be administered in conjunction with other therapies like checkpoint inhibitors and antigen administration for cancer antigens. The antibodies can also be used to reduce an NK cell-mediated immune response to non-self cells or tissues transplanted in an individual, thereby enhancing the effectiveness of therapies such as CAR T-cell therapy.

DATA AVAILABILITY

The inventors have shown specific binding regions and potential for high affinity binding to CD94.

PATENT STATUS

Country	Type	Number	Dated	Case
China	Published Application	116829185	04/05/2024	2020-221

Additional Patents Pending

CONTACT

Gemma E. Rooney
Gemma.Rooney@ucsf.edu
 tel: 415-625-9093.



OTHER INFORMATION

KEYWORDS

CD94, Antibody, Antibodies, NK Cells, CD8+ T cells, CAR-T cell therapy

CATEGORIZED AS

- ▶ [Medical](#)
- ▶ [Disease: Cancer](#)
- ▶ [Therapeutics](#)

RELATED CASES

2020-221-0

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,

San Francisco, CA 94158

innovation@ucsf.edu

<https://innovation.ucsf.edu>

Fax:

© 2024, The Regents of the University of

California

[Terms of use](#) [Privacy Notice](#)